Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02920671 · ClinicalTrials.gov registry record
Muscle OXPHOS and Nutrient Homeostasis
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 45
- Enrollment target
NCT02920671: Completed study, sponsored by University of Pennsylvania.
NCT02920671 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02920671 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
Investigators are recruiting adults (men and women, ages 18 to 65 years, inclusive) with a confirmed genetic diagnosis of mitochondrial disease. Investigators are also recruiting both obese and normal-weight healthy volunteers (men and women, ages 18 to 65 years, inclusive) without a family history of mitochondrial disease to compare to affected individuals. The study involves non-invasive MRI methods and glucose tests to focus on the relationship between mitochondrial disease, obesity, and the risk of diabetes. All study visit procedures will be completed within 2 days, which includes an overnight stay at the Hospital of the University of Pennsylvania. There are no study medications or sedations, and participants will be continually monitored during minimally-invasive procedures (e.g., blood draws). All participants will be able to receive compensation. Furthermore, it may be possible to provide reimbursement for travel, lodging, and meals for individuals with mitochondrial disease. Investigators hope that this research will contribute to the current knowledge of mitochondrial disease and that it will improve diagnostic and treatment approaches.
Primary Outcome
The primary outcome for the present study will be glucose rate of disposal (Rd) during the OGTT\*
Interventions
- OTHER Questionnaires
- OTHER Tracer-enhanced oral glucose tolerance test (OGTT*)
- OTHER Muscle MRI
- OTHER Dual energy x-ray absorptiometry (DXA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-02-14 |
| Est. Completion | 2024-08-28 |
What the finished NCT02920671 record still lists
NCT02920671 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which Questionnaires is the first listed.
NCT02920671 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02920671 about?
NCT02920671 is a clinical study titled "Muscle OXPHOS and Nutrient Homeostasis". Investigators are recruiting adults (men and women, ages 18 to 65 years, inclusive) with a confirmed genetic diagnosis of mitochondrial disease. Investigators are also recruiting both obese and normal-weight healthy volunteers (men and women, ages 18 to 65 years, inclusive) without a family history ...
What is the current status of trial NCT02920671?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2017-02-14. Estimated completion is 2024-08-28.
What interventions are being tested in trial NCT02920671?
The interventions under investigation include: Questionnaires (OTHER), Tracer-enhanced oral glucose tolerance test (OGTT*) (OTHER), Muscle MRI (OTHER), Dual energy x-ray absorptiometry (DXA) (OTHER).
Who is sponsoring clinical trial NCT02920671?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI